Skip to main content
OpenTrials
Completed

NCT Number: NCT01290510

Hyaluronan in the Treatment of Painful Tendinopathy

The primary objective of this study is to evaluate the efficacy and safety of TCHY106 (2% hyaluronan) in the treatment of painful tendinopathy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Zentrum für Orthopädie und Sportmedizin München, Munich, Bavaria, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients between 18 and 75 years of age and good general health condition.
  • Signed written informed consent.
  • Painful tendinopathy since ≥ 6 weeks.
  • Pain according to Visual Analogue Scale (VAS; 100 millimetres (mm)) ≥ 40 mm.
  • Ensured compliance of subjects for study period.

Exclusion criteria

  • Treatment with any investigational product within 4 weeks prior to study entry.
  • Patients with known hypersensitivity to the products (that is active compound and excipients) or any component or procedure used in the study.
  • Severe intercurrent illness (for example: uncontrolled diabetes mellitus, peripheral neuropathy), which in the opinion of the investigator, may put the patient at risk when participating in the study, or affect the patient's ability to take part in the study.
  • Concomitant disease at study relevant site influencing study evaluation.
  • List of diseases or characteristics judged by the investigator to be incompatible with the assessments and/or procedures for the study evaluation.
  • List of concomitant medications not allowed.
  • Patients treated with: systemic and/or local steroids within the last 4 weeks, immunosuppressive drugs within the last 3 months, repeated use of non-steroidal anti-inflammatory drugs (NSAIDs) within the last week or occasional use within 24 hours.
  • Recent history of drug and/or alcohol abuse (within the last 6 months).
  • List of contra-indications to the treatment.
  • Pregnant or lactating females.
  • Fertile women who do not accept the consistent and correct use of highly effective methods of birth control defined as implants, injectables, combined oral contraceptives, intrauterine devices (IUDs), sexual abstinence or vasectomised partner during the treatment period and the first 4 weeks follow-up period.
  • Subjects unable to understand informed consent or having a high probability of non compliance to the study procedures and or non completion of the study according to investigator's judgement.

Treatment and study plan

hyaluronic acid sodium salt

Device

Two injections of 2 % (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.

Primary outcomes

  1. Change from Baseline in Visual Analogue Scale of pain (VAS; 100 millimetres (mm)) on day 35

    Time frame: Baseline and Day 35

Secondary outcomes

  1. Visual Analogue Scale of pain (VAS; 100 mm) on day 7

    Time frame: On Day 7

  2. Visual Analogue Scale of pain (VAS; 100 mm) on day 90

    Time frame: On Day 90

  3. Clinical parameters at baseline

    Time frame: At baseline

    • Redness
    • Warmth
    • Swelling
    • Tenderness on palpation
    • Crepitus on motion
    • Accumulation of tissue fluid

    Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.

  4. Clinical parameters on day 7

    Time frame: On Day 7

    • Redness
    • Warmth
    • Swelling
    • Tenderness on palpation
    • Crepitus on motion
    • Accumulation of tissue fluid

    Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.

  5. Clinical parameters on day 35

    Time frame: On Day 35

    • Redness
    • Warmth
    • Swelling
    • Tenderness on palpation
    • Crepitus on motion
    • Accumulation of tissue fluid

    Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.

  6. Clinical parameters on day 90

    Time frame: On Day 90

    • Redness
    • Warmth
    • Swelling
    • Tenderness on palpation
    • Crepitus on motion
    • Accumulation of tissue fluid

    Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.

  7. Quality of life questionnaire at baseline

    Time frame: At baseline

  8. Quality of life questionnaire on day 7

    Time frame: On Day 7

  9. Quality of life questionnaire on day 35

    Time frame: On Day 35

  10. Quality of life questionnaire on day 90

    Time frame: On Day 90

  11. Patient's and investigator's global evaluation of study-relevant tendon complaints on day 7

    Time frame: On Day 7

    Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition

  12. Patient's and investigator's global evaluation of study-relevant tendon complaints on day 35

    Time frame: On Day 35

    Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition

  13. Patient's and investigator's global evaluation of study-relevant tendon complaints on day 90

    Time frame: On Day 90

    Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition

  14. Frequency of test product-related Adverse Events

    Time frame: Up to Day 90

Sponsors and collaborators

Lead sponsor

TRB Chemedica AG

Industry

Registry information

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Feb 7, 2011
Registry last updated
Sep 22, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.